XR Securities’s AbbVie ABBV Stock Holding History

XR Securities’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,330	Closed	-$195K	–	371
2023 Q1	$212K	Buy	+1,330	New	+$203K	0.01%	378
2022 Q1	–	Sell	-9,475	Closed	-$1.38M	–	345
2021 Q4	$1.28M	Buy	+9,475	New	+$1.12M	0.12%	42
2021 Q3	–	Sell	-5,980	Closed	-$683K	–	399
2021 Q2	$674K	Buy	5,980 +2,902	+94%	+$327K	0.29%	58
2021 Q1	$333K	Sell	3,078 -3,018	-50%	-$323K	0.02%	133
2020 Q4	$653K	Buy	6,096 +2,466	+68%	+$237K	0.04%	72
2020 Q3	$318K	Buy	+3,630	New	+$342K	0.03%	89
2020 Q1	–	Sell	-5,326	Closed	-$454K	–	204
2019 Q4	$472K	Buy	+5,326	New	+$442K	0.06%	78
2019 Q3	–	Sell	-6,073	Closed	-$416K	–	234
2019 Q2	$442K	Sell	6,073 -56	-0.9%	-$4.4K	0.09%	75
2019 Q1	$494K	Buy	+6,129	New	+$501K	0.06%	80
2018 Q4	–	Sell	-6,245	Closed	-$549K	–	351
2018 Q3	$591K	Buy	+6,245	New	+$592K	0.15%	78

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

XR Securities's ABBV Position: Q2 2023 in Review

XR Securities sold out of AbbVie (ABBV) in Q2 2023, closing a stake of 1,330 shares — an estimated $195K sold.

XR Securities first reported a position in ABBV in Q3 2018 and held it in 10 quarters. The position peaked at $1.28M in Q4 2021. 3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

XR Securities reported no remaining AbbVie position as of Q2 2023 after selling out during the quarter.
XR Securities sold 1,330 AbbVie shares in Q2 2023, an estimated $195K.
XR Securities first reported a position in AbbVie in Q3 2018 and held it in 10 quarters.
XR Securities's AbbVie position peaked at $1.28M in Q4 2021.
3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on XR Securities's 13F filing for Q2 2023, filed 8 Aug 2023.